Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial

被引:316
作者
Diener, HC
Kronfeld, K
Boewing, G
Lungenhausen, M
Maier, C
Molsberger, A
Tegenthoff, M
Trampisch, HJ
Zenz, M
Meinert, R
机构
[1] Univ Essen Gesamthsch, Dept Neurol, Essen, Germany
[2] Johannes Gutenberg Univ Mainz, Koodinierungszentrum Klin Studien, D-6500 Mainz, Germany
[3] Forsch Grp Akupunktur & Med, Dusseldorf, Germany
[4] Ruhr Univ Bochum, Dept Pain Management, BG Kliniken Bergmannsheil, D-4630 Bochum, Germany
[5] Ruhr Univ Bochum, Dept Neurol, BG Kliniken Bergmannsheil, D-4630 Bochum, Germany
[6] Ruhr Univ Bochum, Dept Med Informat Stat & Epidemiol, D-4630 Bochum, Germany
[7] Ruhr Univ Bochum, Dept Anaesthesiol Intens Care & Pain Therapy, BG Kliniken Bergmannsheil, D-4630 Bochum, Germany
关键词
D O I
10.1016/S1474-4422(06)70382-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Our aim was to assess the efficacy of a part-standardised verum acupuncture procedure, in accordance with the rules of traditional Chinese medicine, compared with that of part-standardised sham acupuncture and standard migraine prophylaxis with beta blockers, calcium-channel blockers, or antiepileptic drugs in the reduction of migraine days 26 weeks after the start of treatment. Methods This study was a prospective, randomised, multicentre, double-blind, parallel-group, controlled, clinical trial, undertaken between April 2002 and July 2005. Patients who had two to six migraine attacks per month were randomly assigned verum acupuncture (n = 313), sham acupuncture (n = 339), or standard therapy (n = 308). Patients received ten sessions of acupuncture treatment in 6 weeks or continuous prophylaxis with drugs. Primary outcome was the difference in migraine days between 4 weeks before randomisation and weeks 23-26 after randomisation. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN52683557. Findings Of 1295 patients screened, 960 were randomly assigned to a treatment group. Immediately after randomisation, 125 patients (106 from the standard group) withdrew their consent to study participation. 794 patients were analysed in the intention-to-treat popoulation and 443 in the per-protocol population. The primary outcome showed a mean reduction of 2 (.) 3 days (95% CI 1(.)9-2(.)7) in the venim acupuncture group, 1(.)5 days (1(.)1-2(.)0) in the sham acupuncture group, and 2(.)1 days (1(.)5-2(.)7) in the standard therapy group. These differences were statistically significant compared with baseline (p < 0(.)0001), but not across the treatment groups (p = 0(.)09). The proportion of responders, defined as patients with a reduction of migraine days by at least 50%, 26 weeks after randomisation, was 47% in the verum group, 39% in the sham acupuncture group, and 40% in the standard group (p = 0(.)133). Interpretation Treatment outcomes for migraine do not differ between patients treated with sham acupuncture, verum acupuncture, or standard therapy.
引用
收藏
页码:310 / 316
页数:7
相关论文
共 22 条
[1]   Acupuncture in the prophylactic treatment of migraine without aura: A comparison with flunarizine [J].
Allais, G ;
De Lorenzo, C ;
Quirico, PE ;
Airola, G ;
Tolardo, G ;
Mana, O ;
Benedetto, C .
HEADACHE, 2002, 42 (09) :855-861
[2]   Is acupuncture analgesia an expectancy effect? Preliminary evidence based on participants' perceived assignments in two placebo-controlled trials [J].
Bausell, RB ;
Lao, LX ;
Bergman, S ;
Lee, WL ;
Berman, BM .
EVALUATION & THE HEALTH PROFESSIONS, 2005, 28 (01) :9-26
[3]   Seeking a simple measure of analgesia for mega-trials: is a single global assessment good enough? [J].
Collins, SL ;
Edwards, J ;
Moore, RA ;
Smith, LA ;
McQuay, HJ .
PAIN, 2001, 91 (1-2) :189-194
[4]   Advances in pharmacological treatment of migraine [J].
Diener, HC ;
Limmroth, V .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (10) :1831-1845
[5]  
DIENER HC, 2003, RECOMMENDATIONS DIAG
[6]   Botulinum toxin type A for the prophylaxis of chronic daily headache: Subgroup analysis of patients not receiving other prophylactic medications: A randomized double-blind, placebo-controlled study [J].
Dodick, DW ;
Mauskop, A ;
Elkind, AH ;
DeGryse, R ;
Brin, MF ;
Silberstein, SD .
HEADACHE, 2005, 45 (04) :315-324
[7]   Changes in chronic pain severity over time: the Chronic Pain Grade as a valid measure [J].
Elliott, AM ;
Smith, BH ;
Smith, WC ;
Chambers, WA .
PAIN, 2000, 88 (03) :303-308
[8]   German Acupuncture Trials (gerac) address problems of methodology associated with acupuncture studies [J].
Endres, HG ;
Zenz, M ;
Schaub, C ;
Molsberger, A ;
Haake, M ;
Streitberger, K ;
Skipka, G ;
Maier, C .
SCHMERZ, 2005, 19 (03) :201-+
[9]   Mechanisms of the placebo response and their impact on clinical trials and clinical practice [J].
Finniss, DG ;
Benedetti, F .
PAIN, 2005, 114 (1-2) :3-6
[10]   THE EPIDEMIOLOGY OF HEADACHE IN GERMANY - A NATIONWIDE SURVEY OF A REPRESENTATIVE SAMPLE ON THE BASIS OF THE HEADACHE CLASSIFICATION OF THE INTERNATIONAL-HEADACHE-SOCIETY [J].
GOBEL, H ;
PETERSENBRAUN, M ;
SOYKA, D .
CEPHALALGIA, 1994, 14 (02) :97-106